Abstract: The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and use of the solid form in the treatment of Janus kinase (JAK) related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.

Abstract: A biaxially-oriented polyethylene (BOPE) multilayer film comprises a skin layer with a matte surface and a core, the skin layer with a matte surface comprising, in weight percent (wt %) based upon the weight of the skin layer: (1) from 20 to 80 wt % of an ethylene-based polymer, and (2) from 80 to 20 wt % of a propylene-based polymer; each of the ethylene-based polymer and the propylene-based polymer having a storage modulus, with a difference between the storage modulus of the ethylene-based polymer and the propylene-based polymer of greater than 40 megaPascals (MPa) at 110° C., and greater than 18 MPa at 120° C.

Abstract: Various methods and systems are provided for x-ray imaging. In one embodiment, a method for an image pasting examination comprises acquiring, via an optical camera and/or depth camera, image data of a subject, controlling an x-ray source and an x-ray detector according to the image data to acquire a plurality of x-ray images of the subject, and stitching the plurality of x-ray images into a single x-ray image. In this way, optimal exposure techniques may be used for individual acquisitions in an image pasting examination such that the optimal dose is utilized, stitching quality is improved, and registration failures are avoided.

Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.

Abstract: A hydrocarbon reservoir is treated with heat to induce gasification, water-gas shift, and/or aquathermolysis reactions to generate gases including hydrogen. The hydrogen alone is produced to the surface by using hydrogen-only membranes in the production wells.

Abstract: The present invention relates to compounds represented by formula (I) and formula (II) and a chiral synthesis and chiral isolation method therefor, further relating to a salt and crystal form of the compound represented by formula (I), a preparation method therefor, a pharmaceutical composition comprising the same, and use thereof in the preparation of a medicament used for the treatment of a viral infectious disease such as hepatitis B.

Abstract: A method and system to treat and dry fines tailings generated from mining operations, comprising spraying the tailings material into a vacuum chamber operated at less than atmospheric pressure to separate evaporated water from the residual solid materials.

Abstract: The invention provides methods for pelletizing bituminous liquids by inducing endogenous asphaltenes in the liquid to form a resilient external membrane on an aliquot of the bituminous liquid, optionally with simultaneous collection of light components that result from the process of inducing endogenous asphaltene formation.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.

Abstract: A petroleum reservoir is treated with heat to induce gasification, water-gas shift, and/or aquathermolysis reactions to generate synthesis gas comprising hydrogen gas. The synthesis gas is produced to the surface using one or more production wells.

Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.

Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.

Abstract: Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Abstract: The invention provides methods for pelletizing oil liquids by inducing endogenous asphaltenes in the liquid to form a resilient external layer on an aliquot of the bituminous liquid.

Abstract: Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.

Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs.

Abstract: The disclosure relates to a bioactive molecule conjugate, preparation methods and use thereof, particularly relates to a novel bioactive molecule conjugate obtained by improving coupling of the drug and the targeting moiety in an ADC or SMDC, as well as its preparation method and use in the manufacture of a medicament for the treatment of a disease associated with an abnormal cell activity.

Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.

Abstract: Provided in the present invention are a compound of Formula (I), a pharmaceutical composition comprising the same, a method for preparing the same, and use thereof as a NS5B polymerase inhibitor, a DNA polymerase inhibitor or a reverse transcriptase inhibitor for the prevention or treatment of viral diseases or cancers.